InsiderTrades.com logo
Your Money is Not Safe
From American Alternative   |   Ad
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
CLICK HERE TO GET YOUR GUIDE NOW
Nancy Stuart net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Nancy Stuart Biography and Net Worth

COO of Concert Pharmaceuticals
Ms. Nancy Stuart has served as our Chief Operating Officer since October 2007 and was our Senior Vice President, Corporate Strategy and Operations from July 2006 to October 2007. Prior to joining Concert Ms. Stuart held various business operations and business development positions at Amgen Inc., a biopharmaceutical company, Kinetix Pharmaceuticals, Inc., a pharmaceutical company subsequently acquired by Amgen, Vertex, a pharmaceutical company and Genzyme Corporation, a biotechnology company subsequently acquired by Sanofi S.A. She also serves on the Board of Directors of KalVista Pharmaceuticals, a pharmaceutical company, and The Greater Boston YMCA. Ms. Stuart holds a B.S. from the University of Michigan, and an M.B.A. from the Simmons College Graduate School of Management.

What is Nancy Stuart's net worth?

The estimated net worth of Nancy Stuart is at least $2.20 million as of February 15th, 2023. Ms. Stuart owns 262,596 shares of Concert Pharmaceuticals stock worth more than $2,197,929 as of April 25th. This net worth estimate does not reflect any other assets that Ms. Stuart may own. Learn More about Nancy Stuart's net worth.

How do I contact Nancy Stuart?

The corporate mailing address for Ms. Stuart and other Concert Pharmaceuticals executives is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. Concert Pharmaceuticals can also be reached via phone at (781) 860-0045 and via email at [email protected]. Learn More on Nancy Stuart's contact information.

Has Nancy Stuart been buying or selling shares of Concert Pharmaceuticals?

Nancy Stuart has not been actively trading shares of Concert Pharmaceuticals within the last three months. Most recently, Nancy Stuart sold 6,048 shares of the business's stock in a transaction on Wednesday, February 15th. The shares were sold at an average price of $8.33, for a transaction totalling $50,379.84. Following the completion of the sale, the chief operating officer now directly owns 262,596 shares of the company's stock, valued at $2,187,424.68. Learn More on Nancy Stuart's trading history.

Who are Concert Pharmaceuticals' active insiders?

Concert Pharmaceuticals' insider roster includes Marc Becker (CFO), James Cassella (Insider), Jeffrey Munsie (Insider), Nancy Stuart (COO), and Roger Tung (CEO). Learn More on Concert Pharmaceuticals' active insiders.

Nancy Stuart Insider Trading History at Concert Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2023Sell6,048$8.33$50,379.84262,596View SEC Filing Icon  
1/30/2023Sell13,200$8.35$110,220.00268,644View SEC Filing Icon  
1/6/2023Sell2,893$7.25$20,974.25281,844View SEC Filing Icon  
2/14/2022Sell6,049$3.08$18,630.92View SEC Filing Icon  
1/5/2022Sell2,894$3.19$9,231.86View SEC Filing Icon  
2/16/2021Sell6,049$7.32$44,278.68173,280View SEC Filing Icon  
6/22/2020Sell10,295$11.34$116,745.30167,924View SEC Filing Icon  
7/10/2018Sell31,418$17.87$561,439.66116,085View SEC Filing Icon  
11/2/2015Sell23,216$24.29$563,916.6425,004View SEC Filing Icon  
3/11/2015Sell46,430$15.00$696,450.00View SEC Filing Icon  
See Full Table

Nancy Stuart Buying and Selling Activity at Concert Pharmaceuticals

This chart shows Nancy Stuart's buying and selling at Concert Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Concert Pharmaceuticals Company Overview

Concert Pharmaceuticals logo
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $8.37
Low: $8.37
High: $8.37

50 Day Range

MA: $8.37
Low: $8.33
High: $8.40

2 Week Range

Now: $8.37
Low: $2.66
High: $8.55

Volume

N/A

Average Volume

2,970,800 shs

Market Capitalization

$401.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52
This Apple-like Innovator is Revolutionizing Healthcare
From Wall Street Star   |   Ad
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Click here to learn more about the booming eHealth industry